Agenus Inc. (AGEN)

Agenus's stock price has been impacted by several key events over the past six months. In Q4 2025, the company reported earnings per share of -$0.37, beating analysts' expectations, and revenue for the quarter was $34.2 million, also surpassing estimates. The company swung to a profit in Q3 FY 2025, reporting total revenue of US$30.2 million and EPS of US$2.00. Agenus announced the first patient enrollment in the global Phase 3 BATTMAN trial for BOT plus BAL in metastatic colorectal cancer in May 2026. In April 2026, Agenus announced that four abstracts highlighting botensilimab, alone or in combination with balstilimab, were accepted for presentation at the 2026 ASCO Annual Meeting, including the first Phase 2 data in advanced cutaneous melanoma. Phase II data demonstrating immune reprogramming and durable survival with botensilimab, balstilimab, and agenT-797 in PD-1 refractory gastroesophageal cancer were also reported in April 2026. Agenus entered into a strategic collaboration with Zydus Lifesciences, involving the sale of biologics manufacturing facilities for $75 million upfront, contingent payments, an equity investment by Zydus, and an exclusive license for BOT and BAL in India and Sri Lanka. The share price has been highly volatile over the past three months, with an average weekly change of 22%, and was up 113% over the past year as of May 7, 2026.

Demand seasonality for Agenus is influenced by the broader Healthcare sector, which generally exhibits strength from April 25 to December 4. Historical seasonal chart analysis suggests a "Buy Date" of March 31 and a "Sell Date" of July 5, which has historically resulted in outperformance compared to the S&P 500 Total Return Index over the past 20 years.

Agenus, Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases, operating within the Healthcare sector and Biotechnology industry. The company specializes in immuno-oncology, aiming to activate innate and adaptive immunity to overcome tumor immune evasion. Key products and pipeline candidates include Botensilimab, a human Fc-enhanced multifunctional anti-CTLA-4 antibody; Balstilimab, a novel, fully human monoclonal antibody designed to block PD-1; Retrocyte Display, an antibody expression platform; QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant; Prophage Series, personalized anti-cancer vaccines; and other clinical-stage immuno-oncology assets.

Agenus, Inc. is headquartered in Lexington, Massachusetts, USA. The company operates primarily in the United States, with a global clinical operations footprint, and has strategic collaborations including licensing agreements in regions like India and Sri Lanka.

Agenus's brand reputation has been positively influenced by advancements in immuno-oncology and strategic initiatives. The demonstration of robust and durable responses of botensilimab and balstilimab across various hard-to-treat cancers has bolstered its scientific and clinical standing. The FDA's renewed focus on accelerating cures and positive regulatory sentiment for its candidates in markets outside the U.S. suggests a favorable environment for Agenus's products. The partnership with Zydus Lifesciences highlights Agenus's ability to forge strategic alliances and expand its global footprint. Regular presentations of clinical progress at major oncology congresses enhance its visibility and credibility.

Agenus Inc. is a publicly traded company on NASDAQ under the ticker AGEN with a diverse ownership structure. As of May 6, 2026, Agenus had 96 institutional owners and shareholders, including Vanguard Group Inc., Siren, L.L.C., and BlackRock, Inc. As of March 31, 2025, institutional investors held approximately 26.11% of the company's stock. Insider ownership stood at 0.74% in April 2025, while GuruFocus data indicates insider ownership at 19.58%. Public companies and individual investors own approximately 63.21% of the company's stock. Dr. Garo H. Armen is the Chairman and CEO, and Jennifer Buell is the President and COO.